Cover Image
市場調查報告書

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF) :開發中產品分析

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363578
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF) :開發中產品分析 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 84 Pages
簡介

本報告提供顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF)的概要

治療藥的開發

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中的產品 - 各開發階段

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中的產品 - 各治療範圍

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中的產品 - 各適應症

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):企業開發中的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):大學/機關開發中的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF)的治療藥的開發企業

  • Aduro BioTech, Inc.
  • Amgen Inc.
  • BriaCell Therapeutics Corp.
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • KaloBios Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Sillajen Biotherapeutics
  • 武田藥品工業

藥物簡介

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):暫停中的計劃

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中止的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0385TDB

Summary

Global Markets Direct's, 'Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2016', provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted pipeline therapeutics.

The report provides comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Overview
  • Therapeutics Development
    • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Stage of Development
    • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Therapy Area
    • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Indication
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Companies
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Universities/Institutes
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
    • Aduro BioTech, Inc.
    • Amgen Inc.
    • BriaCell Therapeutics Corp.
    • GlaxoSmithKline Plc
    • Humabs BioMed SA
    • KaloBios Pharmaceuticals, Inc.
    • Morphotek, Inc.
    • Sillajen Biotherapeutics
    • Takeda Pharmaceutical Company Limited
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
    • GSK-3196165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenzilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MORAb-022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • namilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OrienX-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexastimogene devacirepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STINGVAX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVBR-1GM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • talimogene laherparepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Projects
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Featured News & Press Releases
    • May 31, 2016: Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
    • May 18, 2016: Amgen To Present Data on IMLYGIC (talimogene laherparepvec) At ASCO 2016
    • May 18, 2016: BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
    • May 16, 2016: SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec
    • Apr 18, 2016: GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis
    • Apr 12, 2016: BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity
    • Apr 05, 2016: BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
    • Mar 29, 2016: SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
    • Mar 29, 2016: BriaCell Discovers Gene Signature of BriaVax Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial
    • Mar 16, 2016: NICE consults on 'no' recommendation for skin cancer drug talimogene laherparepvec
    • Jan 05, 2016: SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
    • Dec 20, 2015: Moffitt Cancer Center And UC Davis Suspends Clinical Trial Of KaloBios' Leukemia Drug
    • Dec 17, 2015: European Commission Approves Amgen's IMLYGIC (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
    • Dec 07, 2015: Morphotek Announces Phase 1 Results From MORAb-022-001 Trial in Healthy Subjects and Patients with Mild-to-Moderate Rheumatoid Arthritis
    • Nov 16, 2015: Amgen to Present IMLYGIC (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Aduro BioTech, Inc., H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by BriaCell Therapeutics Corp., H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by Humabs BioMed SA, H2 2016
  • Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
  • Pipeline by Morphotek, Inc., H2 2016
  • Pipeline by Sillajen Biotherapeutics, H2 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top